Salazar LMÁ

Idioma: Español
Referencias bibliográficas: 15
Paginas: 4-5
Archivo PDF: 39.80 Kb.

FRAGMENTO

La neumonía adquirida en la comunidad (NAC) sigue siendo una importante causa de morbimortalidad en todo el mundo a pesar de los avances en la ciencia médica. La incidencia de NAC varía de 2 a 5 casos por 100,000 habitantes, y es la principal causa de muerte debido a una infección a través del mundo. Aproximadamente, cuatro millones de casos ocurren anualmente en los Estados Unidos, siendo Streptococcus pneumoniae el patógeno más frecuentemente encontrado.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Mandell LA. Antimicrobial resistance and treatment of community-acquired pneumonia. Clin Chest Med 2005;26:57-64.

2. Nathawani D, Rubinstein E, Barlow G, Davey P. Do guidelines for community-acquired pneumonia improve the cost-effectiveness of hospital care? Clin Infect Dis 2001;32:728-741.

3. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730-1754.

4. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:S27-S72.

5. Lim WS, Baudouin SV, George RC, et al. BTS guidelines of the management of community acquired pneumonia in adults: update 2009. Thorax 2009;64;iii1-iii55.

6. Höffken G, Lorenz J, Kern W, et al. Guidelines of the Paul-Ehrlich-Society of Chemotherapy, the German Respiratory Diseases Society, the German Infectious Diseases Society and the Compentence Network CAPNETZ for the Management of Lower Respiratory Tract Infections and Community-acquired Pneumonia. Pneumonologie 2010;64:149-154.

7. Valencia M, Badia JR, Cavalcanti M, et al. Pneumonia severity index class V patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores. Chest 2007;132:515-522.

8. Phua J, See KC, Chan YH, et al. Validation and clinical implications of the IDSA/ATS minor criteria for severe community-acquired pneumonia. Thorax 2009;64:598-603.

9. McNally M, Curtain J, O’Brien KK, Dimitrov BD, Fahey T. Validity of British Thoracic Society guidance (the CRB-65 rule) for predicting the severity of pneumonia in general practice: systematic review and meta-analysis. Br J Gen Pract 2010;60:e423-433 doi: 10.3399/bjgp10X532422.

10. Loke YK, Kwok CS, Niruban A, Myint PK. Value of severity scales in predicting mortality from community-acquired pneumonia: systematic review and meta-analysis. Thorax 2010;65:884-890.

11. McCormick D, Fine MJ, Coley C, et al. Variation in length of hospital stay in patients with community-acquired pneumonia: are shorter stays associated with worse medical outcomes? Am J Med 1999;107:5-12.

12. Garau J, Baquero F, Pérez-Trallero E, et al. NACER Group. Factors impacting on lenght of stay and mortality of community-acquired pneumonia. Clin Microbiol Infect 2008;14:322-329.

13. Huang JQ, Hooper PM, Marrie TJ. Factors associated with length of stay in hospital for suspected community-acquired pneumonia. Can Respir J 2006;13:317-324.

14. Menéndez R, Torres A, Reyes S. Initial management of pneumonia and sepsis: factors associated with improved outcome. Eur Respir J 2012;39:156-162.

15. Báez SR, Gómez ZC, López EC, et al. Neumonía adquirida en la comunidad. Revisión y actualización con una perspectiva orientada a la calidad de la atención médica. Neumol Cir Torax 2013;72 Supl 1:6-43.